It has been reported that DUXAP8 enhances GC cell proliferation and tumorigenesis, partly by epigenetically silencing PLEKHO1 expression through binding to PRC2, making it a potential biomarker for GC diagnosis and therapy 54. Here, DUXAP8 is linked to gastric cancer.